Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?


C. Lacroix, R. Guilhaumou, J. Micallef, G. Bruneteau, C. Desnuelle , O. Blin


July 16,  2023


Cannabis may have therapeutic benefits to relieve symptoms of amyotrophic lateral sclerosis (ALS) thanks to its pleiotropic pharmacological activity. This study is the first to present a large questionnaire-based survey about the “real-life” situation regarding cannabis use in the medical context in ALS patients in France. There were 129 respondents and 28 reported the use of cannabis (21.7%) to relieve symptoms of ALS. Participants mostly reported the use of cannabidiol (CBD) oil and cannabis weed and declared benefits both on motor (rigidity, cramps, fasciculations) and non-motor (sleep quality, pain, emotional state, quality of life, depression) symptoms and only eight reported minor adverse reactions (drowsiness, euphoria and dry mouth). Even if cannabis is mostly used outside medical pathways and could expose patients to complications (street and uncontrolled drugs, drug-drug interactions, adverse effects…), most of the participants reported “rational” consumption (legal cannabinoids, with only few combustion and adverse reactions). Despite some limitations, this study highlights the need for further research on the potential benefits of cannabis use for the management of ALS motor and non-motor symptoms. Indeed, there is an urgent need and call for and from patients to know more about cannabis and secure its use in a medical context.

DOI: 10.1016/j.neurol.2023.03.018


Lacroix, C., Guilhaumou, R., Micallef, J., Bruneteau, G., Desnuelle, C., & Blin, O. (2023). Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?. Revue Neurologique.